|
๐ก-๐ก๐ถ๐๐ฟ๐ผ๐๐ฎ๐บ๐ถ๐ป๐ฒ ๐๐ผ๐ฟ๐บ๐ฎ๐๐ถ๐ผ๐ป ๐ถ๐ป ๐ฃ๐ต๐ฎ๐ฟ๐บ๐ฎ๐ฐ๐ฒ๐๐๐ถ๐ฐ๐ฎ๐น ๐๐ฟ๐๐ด ๐ฃ๐ฟ๐ผ๐ฑ๐๐ฐ๐๐: ๐๐ฒ๐๐ฒ๐น๐ผ๐ฝ๐บ๐ฒ๐ป๐ ๐ฎ๐ป๐ฑ ๐ฉ๐ฎ๐น๐ถ๐ฑ๐ฎ๐๐ถ๐ผ๐ป ๐ผ๐ณ ๐ฎ ๐๐ถ๐ฎ๐๐ฒ๐ฑ, ๐๐ผ๐ป๐๐ฒ๐ฟ๐๐ฎ๐๐ถ๐๐ฒ, ๐ฃ๐ฟ๐ฒ๐ฑ๐ถ๐ฐ๐๐ถ๐๐ฒ ๐ ๐ผ๐ฑ๐ฒ๐น
|
|
1
|
333
|
November 26, 2025
|
|
N-Nitrosamine Formation in Pharmaceutical Drug Products: Development and Validation of a Biased, Conservative, Predictive Model-Pub
|
|
4
|
458
|
November 24, 2025
|
|
In Vitro Metabolism Study of NDSRIs
|
|
3
|
279
|
November 20, 2025
|
|
Studies addressing potential bioactivation and genotoxicity liabilities of the N-nitroso derivative of the antidepressant paroxetine-Pub
|
|
0
|
112
|
November 18, 2025
|
|
N-Nitroso Sertraline
|
|
9
|
945
|
October 23, 2025
|
|
Analytical challenge for determination of instable standard of other N-nitroso structure
|
|
10
|
794
|
September 22, 2025
|
|
Modeling the Impact of Excipients Selection on Nitrosamine Formation towards Risk Mitigation
|
|
18
|
5145
|
September 20, 2025
|
|
Nitrosamines risk in cleaning validation approach
|
|
11
|
371
|
September 4, 2025
|
|
Ask for help with limit for Nitroso-olaparib
|
|
2
|
238
|
September 4, 2025
|
|
๐จโ๐ป Quantitative Analysis of NDMA, N-Nitroso-l-ephedrine and N-Nitroso-pseudoephedrine in Pseudoephedrine Hydrochloride by HPLC-Tandem MS
|
|
2
|
525
|
August 28, 2025
|
|
Three-Pronged Approach (Active Pharmaceutical Ingredients, Excipients, and NOx-Free Air) Successfully Suppressed the Formation of Nitroso-atomoxetine to 0.097 ppm
|
|
0
|
463
|
August 24, 2025
|
|
Primary amines in formation of nitrosamine
|
|
6
|
1002
|
August 13, 2025
|
|
Nitrosamine Risk Mitigation Calculator (by DFE Pharma)
|
|
1
|
1217
|
August 11, 2025
|
|
๐บ๐ธ FDA - Fiscal Year 2024 Generic Drug Science and Research Initatives Public Workshop
|
|
21
|
2140
|
August 7, 2025
|
|
Highlights from the 13th meeting of the Nitrosamine Implementation Oversight Group (NIOG)
|
|
7
|
511
|
July 22, 2025
|
|
Genotoxicity evaluation of ten nitrosamine drug substance-related impurities using 2D and 3D HepaRG cells -Pub
|
|
0
|
269
|
July 12, 2025
|
|
CMO Nitrosamine Risk Assessment
|
|
7
|
506
|
June 27, 2025
|
|
Analytical Method Development Strategy for Controlling Two New Nitrosamine Drug Substance Related Impurities (NDSRIs) in a Pharmaceutical Drug Product for Treatment of a Rare Disease -Pub
|
|
0
|
123
|
June 25, 2025
|
|
Optimizing Pharmaceutical Formulations: Strategies for Improving Stability and Minimizing Nitrosamine Impurities-Webinar
|
|
1
|
344
|
June 20, 2025
|
|
Using N-Nitrosodiethanolamine (NDELA) and N-Nitrosopiperidine (NPIP) Transgenic Rodent Gene Mutation Data and Quantum Mechanical Modeling to Derive Potency-Based Acceptable Intakes for NDSRIs Lacking Robust Carcinogenicity Data-Pub
|
|
0
|
241
|
June 6, 2025
|
|
ยนโตN-Enriched NAP Test
|
|
0
|
246
|
May 31, 2025
|
|
N-nitroso Torasemide Impurity formation and control
|
|
33
|
2623
|
May 27, 2025
|
|
Optimizing the detection of N-nitrosamine mutagenicity in the Ames test -Pub
|
|
17
|
805
|
May 23, 2025
|
|
N-Nitroso Spinosad Impurity-A and Impurity-D
|
|
2
|
244
|
May 21, 2025
|
|
๐ฒ๐ฝ Free Lhasa Mรฉxico Symposia: Shaping the Future of Pharma & Regulation ๐ฒ๐ฝ
|
|
0
|
133
|
May 13, 2025
|
|
Understanding Aqueous Nitrosation Kinetics of 4-Substituted Piperidines To Risk Assess Pharmaceutical Processes and Products-Pub
|
|
1
|
242
|
May 6, 2025
|
|
๐
Updates on Approaches to Acceptable Intakes of Nitrosamine Drug Substance Related Impurities (NDSRIs) and Bioequivalence Assessment for Reformulated Drug Products(CRCG)
|
|
39
|
3614
|
May 2, 2025
|
|
Autonomous CPCA Web-based calculator FREE
|
|
33
|
6842
|
April 30, 2025
|
|
N-nitroso-deucravacitinib
|
|
9
|
513
|
April 29, 2025
|
|
๐ต๐ป OTC Market Withdrawal of Diphenhydramine
|
|
0
|
647
|
April 24, 2025
|